Introduction
Johnson &
Johnson is the American company, engaged in the research and development,
manufacture and sale of a broad range of health care products. Being a public
company, Johnson & Johnson (J&J) is listed on the NYSE and its common
stock is a part of the Dow Jones Industrial Average. The list of the products
varies, however its main attention is concentrated mainly on H&S goods.
Description of the Organization
The corporation conducts business in 60
countries of the world focusing on the production of the goods related to human
health and well-being. With more than 250 subsidiary companies
worldwide J&J Corporation employs approximately 118,000 people having the
headquarters in New Jersey, United States.
Today the key
persons in the life of the company are the chairman of the board, William
Weldon, and CEO, Alex Gorsky.
Founded in 1886
by the Johnson’s brothers, the company started with a production of
ready-to-use surgical dressings. In 1920s the list of the products expanded when
the company begun to manufacture skin and hair care. In 1941 a separate
division for surgical products was created, which later became known under the
title of Ethicon. In 1970s the corporation launched a line of products for
women’s health care needs and toiletries. Later the shelves of the stores all
around the world were loaded with baby care goods. And in recent years, J&J
has expanded into such areas as biopharmaceuticals, orthopedic devices, nutritionals
and internet publishing.
According to
J&J official website the sales by international companies were $65.0
billion in 2011, $61.6.0 billion in 2010 and $61.9.4 billion in 2009. This makes an increase of 5.6% in 2011, a decrease of 1.4% in 2010 and increase
of 1.0% in 2009 (Johnson and Johnson Annual Report).
The Company is identified
to have a tall organisational structure. It is organized into three core business
segments: Consumer, Pharmaceutical and Medical Devices and Diagnostics, each of
which has more departments in a command.
·
Consumer branch includes a broad range of products used in
the baby care, skin care, oral care, wound care and women’s health care fields,
as well as nutritional and over-the-counter pharmaceutical products and
wellness and prevention platforms. These products are marketed to the general
public and sold both to retail outlets and distributors throughout the world.
·
The Pharmaceutical segment includes products in the following
areas: anti-infective, antipsychotic, contraceptive, dermatology,
gastrointestinal, hematology, immunology, neurology, oncology, pain management
and virology. These products are distributed directly to retailers, wholesalers
and health care professionals for prescription use.
·
The Medical Devices and Diagnostics segment includes a broad
range of products distributed to wholesalers, hospitals and retailers used in
the professional fields by physicians, nurses, therapists, hospitals,
diagnostic laboratories and clinics. These products include Biosense Webster’s
electrophysiology products; Cordis’ circulatory disease management products;
DePuy’s orthopaedic joint reconstruction, spinal care, neurological and sports
medicine products; Ethicon’s surgical
care, aesthetics and women’s health products; Ethicon Endo-Surgery’s minimally
invasive surgical products and advanced sterilization products; LifeScan’s
blood glucose monitoring and insulin delivery products; Ortho-Clinical
Diagnostics’ professional diagnostic products and Vistakon’s disposable contact
lenses.
External Structure
The Company uses
financial instruments to manage the impact of foreign exchange rate changes on
cash flows. J&J enters into forward foreign exchange contracts to protect
the value of certain foreign currency assets and liabilities and to hedge
future foreign currency transactions primarily related to product costs
(Johnson and Johnson Annual Report). Gains or losses on these contracts are
offset by the gains or losses on the underlying transactions. A 10%
appreciation of the U.S. Dollar from the January 2, 2011 market rates would
increase the unrealized value of the Company’s forward contracts by $239 million.
Conversely, a 10% depreciation of the U.S. Dollar from the January 2, 2011
market rates would decrease the unrealized value of the Company’s forward
contracts by $292 million. The chief financial officer of J&J, Dominic
Caruso in the annual report explained that in either scenario, “the gain or
loss on the forward contract would be offset by the gain or loss on the
underlying transaction, and therefore, would have no impact on future
anticipated earnings and cash flows”.
The Company does
not enter into financial instruments for trading or speculative purposes. J&J
corporation has a strict policy of only entering into contracts with parties
that have at least an “A” (or equivalent) credit rating. The counterparties to
these contracts are major financial institutions and there is no significant
concentration of exposure with any counterparty. “Management believes the risk
of loss is remote” (J&J official website).
Long term vision
is very important to the company and hence on the 125th anniversary Johnson and
Johnson announced of their ambitious five-year plan which will lead the company
to a new sustainable and environmentally friendly direction (PlanetSave.com).
The plan itself goes under the name - The Healthy Future 2015. According to the
report that was published on the official website, the company tends to create
affordable access to HIV and TB treatment in third world nations and less
developed countries. Also J&J plans to donate medicine for treating
intestinal worms to over 30 countries through the Healthy Future 2015.
During the five
year plan the company intends to reduce CO2 emissions, waste disposal and water
usage by developing and introducing to the world 60 new sustainable products.
It is promised that each of those new products will be "eco-friendly and
meet Johnson & Johnson rigorous sustainability innovation criteria" (PlanetSave.com).
Internal
and External Environment of Johnson & Johnson
SWOT
Analysis
Positive
|
Negative
|
|
Internal
|
Strengths:
·
Offers diversified products including baby cares, women’s sanitary
products, orthopedic devices, surgical products as well as internet
publishing
·
Significant sales and marketing capabilities
·
In the process of development of oncology segment
·
Global sales of its products
·
Brand loyalty and brand image as a result of the corporation being known
since 1886
·
J&J has successfully differentiated itself from competitors
·
J&J has more than 29,925 internet domains
·
Receives a support from non-pharmaceutical divisions
·
Introduction of Health Future 2015 brings more customers to the till
as nowadays more people are aware of health issues.
|
Weaknesses
·
43 children over-the-counter children’s medicines were voluntary
recalled, as US revealed: “some products may not fully meet the required manufacturing
specifications”
· In 2010 J&J recalled ASP (Articular
Surface Replacement) hip prostheses from the market due to the percentage
increase in fail prostheses
· The corporation wastes a lot of
money and time researching and hunting for information (workers waste time
replying cyclical enquiries, according to mba-lectures.com)
· The corporation depends highly
on the revenue of Risperdal (medicine for schizophrenia)
· J&J faces strong pressure to
reduce prices and preserve copyright expirations
|
External
|
Opportunities
·
Acquisition of Pfizer by J&J will help in a further growth and a
development of pharmaceutical branch
·
J&J can increase market share by product development and product
innovation globally
·
Expansion and innovation of diagnostics and medical devices
·
Acquisition of other pharmaceutical companies which trigger a growth
of J&J corporation
|
Threats
·
J&J has strong global competitors
·
Has a very low market growth rate
·
Damage of the brand due to the recalls
·
Weaker consumer environment is expected in US (news.com)
·
Makes investments into non-core areas, such as social media with
Maya’s Mom
|
PEST
analysis
|
|
|
Social
Environment
Another major social change
affecting Johnson & Johnson is the phenomenon of surging rates of
various health problems, especially in developed societies but spreading
worldwide, from obesity and diabetes to cancer and mental disorders. Though
highly problematic for society, companies in medicine-related industries
such as Johnson & Johnson are finding themselves with an increasing
number of people to treat and cure. As a company that invests heavily in
research and development, Johnson & Johnson has the opportunity to lead
the way in finding ways to address these serious public health issues.
J&J
In response to a falling birth rate,
companies like J&J, involved with the provision of baby-care products, have
effectively targeted these products at an adult female audience. For
example, their baby lotion is now marketed as being kind and gentle to
women’s skin, as well as that of babies. This represents a response to
changes in the general environment that directly affect their industry.
|
|
Impact of the Structure on the performance of the
Organization
In the mid of 80s
of the last century many companies began experiencing the problems with
managing the control over the production. Just like those companies, Johnson
and Johnson was utilizing the old system of business management that in 1982
nearly had brought the company to its break down. J&J was relying onto the
main four success factors, among which were: size role clarity, control and
specialization However very soon the corporation had realized that there was a
need to consider a new set of the factors, such as: speed, flexibility,
integration and innovation.
Since then,
Johnson & Johnson in order to achieve its goals and reach the vision used a
Decentralized Management Approach. It is big and small at the same time. For
instance each of its operating companies functions as its own small business.
They are strongly entrepreneurial in character, and they know that their
success depends on anticipating customers’ needs and delivering meaningful,
high-quality solutions.
Johnson &
Johnson focuses on the fundamentals of the business and makes sure that the
companies balance the short-term and the long-term in their strategic planning.
The Corporation invests in promising new businesses while maintaining
leadership positions in high growth businesses. It is also focused on
sustainability, and constantly reviews key economic, environmental, and
employee health and safety indicators to ensure that it is on the right path.
Over the last year J&J established an internal innovation fund to keep the
company at the leading edge of transforming health and well-being.
Conclusion:
Johnson and
Johnson is recognized to be the sixth largest consumer health company as well
as the company that provides the world's largest and most diverse medical and
diagnostic devises.
Johnson & Johnson's brands include numerous household names of
medications and first aid supplies. Each year the number of employees increases
with the same bringing the corporation one level higher. The introduction of
the Heath Future 2015 project was another proof for customers that the company
cares for the quality of the products and services it delivers every day.
J&J revises its vision on regular bases and expands its production
to more and more countries. Such strategy gives the company an opportunity to
identify the problems and eventually find a solution to them, with the same
building a more trustworthy corporation and bringing more customers to the till
all around the globe.
Related articles:
JOHNSON & JOHNSON II.HR
Related articles:
JOHNSON & JOHNSON II.HR
Your design and pics of the blog is really nice. More over the content is also very productive. Information you have provided is really very beneficial.and keep posting
ОтветитьУдалитьFor more information :
Latest prosthetic Products india
prosthetic orthopedic care Products
India Orthotic Service Company
Cervical Aids
Body Belts and Braces
Fracture Aids
knee Supports
Wrist and Forearm
Traction Kits
Physiotherapy Aids
walking Aids